Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade Article Swipe
Zia Khan
,
Christian Hammer
,
Jonathan Carroll
,
Flavia Di Nucci
,
Sergio Ley Acosta
,
Vidya Maiya
,
Tushar Bhangale
,
Julie Hunkapiller
,
Ira Mellman
,
Matthew L. Albert
,
Mark I. McCarthy
,
G. Scott Chandler
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1038/s41467-021-23661-4
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1038/s41467-021-23661-4
Related Topics
Concepts
Atezolizumab
Medicine
Autoimmunity
Blockade
Immune system
Adverse effect
Oncology
Genome-wide association study
Immune checkpoint
Immunology
Internal medicine
Immunotherapy
Single-nucleotide polymorphism
Pembrolizumab
Genotype
Biology
Receptor
Genetics
Gene
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1038/s41467-021-23661-4
- https://www.nature.com/articles/s41467-021-23661-4.pdf
- OA Status
- gold
- Cited By
- 82
- References
- 42
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3172878730
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3172878730Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1038/s41467-021-23661-4Digital Object Identifier
- Title
-
Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockadeWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-06-07Full publication date if available
- Authors
-
Zia Khan, Christian Hammer, Jonathan Carroll, Flavia Di Nucci, Sergio Ley Acosta, Vidya Maiya, Tushar Bhangale, Julie Hunkapiller, Ira Mellman, Matthew L. Albert, Mark I. McCarthy, G. Scott ChandlerList of authors in order
- Landing page
-
https://doi.org/10.1038/s41467-021-23661-4Publisher landing page
- PDF URL
-
https://www.nature.com/articles/s41467-021-23661-4.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.nature.com/articles/s41467-021-23661-4.pdfDirect OA link when available
- Concepts
-
Atezolizumab, Medicine, Autoimmunity, Blockade, Immune system, Adverse effect, Oncology, Genome-wide association study, Immune checkpoint, Immunology, Internal medicine, Immunotherapy, Single-nucleotide polymorphism, Pembrolizumab, Genotype, Biology, Receptor, Genetics, GeneTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
82Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 18, 2024: 23, 2023: 23, 2022: 16, 2021: 2Per-year citation counts (last 5 years)
- References (count)
-
42Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3172878730 |
|---|---|
| doi | https://doi.org/10.1038/s41467-021-23661-4 |
| ids.doi | https://doi.org/10.1038/s41467-021-23661-4 |
| ids.mag | 3172878730 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/34099659 |
| ids.openalex | https://openalex.org/W3172878730 |
| fwci | 6.70921559 |
| mesh[0].qualifier_ui | Q000008 |
| mesh[0].descriptor_ui | D061067 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | administration & dosage |
| mesh[0].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[1].qualifier_ui | Q000009 |
| mesh[1].descriptor_ui | D061067 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | adverse effects |
| mesh[1].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[2].qualifier_ui | Q000627 |
| mesh[2].descriptor_ui | D061067 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | therapeutic use |
| mesh[2].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[3].qualifier_ui | Q000276 |
| mesh[3].descriptor_ui | D015551 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | immunology |
| mesh[3].descriptor_name | Autoimmunity |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D005260 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Female |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D014644 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Genetic Variation |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D006801 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Humans |
| mesh[7].qualifier_ui | Q000139 |
| mesh[7].descriptor_ui | D007037 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | chemically induced |
| mesh[7].descriptor_name | Hypothyroidism |
| mesh[8].qualifier_ui | Q000276 |
| mesh[8].descriptor_ui | D007037 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | immunology |
| mesh[8].descriptor_name | Hypothyroidism |
| mesh[9].qualifier_ui | Q000008 |
| mesh[9].descriptor_ui | D000082082 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | administration & dosage |
| mesh[9].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[10].qualifier_ui | Q000009 |
| mesh[10].descriptor_ui | D000082082 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | adverse effects |
| mesh[10].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[11].qualifier_ui | Q000627 |
| mesh[11].descriptor_ui | D000082082 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | therapeutic use |
| mesh[11].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D053208 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Kaplan-Meier Estimate |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D015201 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Meta-Analysis as Topic |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D012189 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Retrospective Studies |
| mesh[15].qualifier_ui | Q000139 |
| mesh[15].descriptor_ui | D013959 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | chemically induced |
| mesh[15].descriptor_name | Thyroid Diseases |
| mesh[16].qualifier_ui | Q000276 |
| mesh[16].descriptor_ui | D013959 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | immunology |
| mesh[16].descriptor_name | Thyroid Diseases |
| mesh[17].qualifier_ui | Q000188 |
| mesh[17].descriptor_ui | D064726 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | drug therapy |
| mesh[17].descriptor_name | Triple Negative Breast Neoplasms |
| mesh[18].qualifier_ui | Q000235 |
| mesh[18].descriptor_ui | D064726 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | genetics |
| mesh[18].descriptor_name | Triple Negative Breast Neoplasms |
| mesh[19].qualifier_ui | Q000276 |
| mesh[19].descriptor_ui | D064726 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | immunology |
| mesh[19].descriptor_name | Triple Negative Breast Neoplasms |
| mesh[20].qualifier_ui | Q000008 |
| mesh[20].descriptor_ui | D061067 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | administration & dosage |
| mesh[20].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[21].qualifier_ui | Q000009 |
| mesh[21].descriptor_ui | D061067 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | adverse effects |
| mesh[21].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[22].qualifier_ui | Q000627 |
| mesh[22].descriptor_ui | D061067 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | therapeutic use |
| mesh[22].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[23].qualifier_ui | Q000276 |
| mesh[23].descriptor_ui | D015551 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | immunology |
| mesh[23].descriptor_name | Autoimmunity |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D005260 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Female |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D014644 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Genetic Variation |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D006801 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Humans |
| mesh[27].qualifier_ui | Q000139 |
| mesh[27].descriptor_ui | D007037 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | chemically induced |
| mesh[27].descriptor_name | Hypothyroidism |
| mesh[28].qualifier_ui | Q000276 |
| mesh[28].descriptor_ui | D007037 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | immunology |
| mesh[28].descriptor_name | Hypothyroidism |
| mesh[29].qualifier_ui | Q000008 |
| mesh[29].descriptor_ui | D000082082 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | administration & dosage |
| mesh[29].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[30].qualifier_ui | Q000009 |
| mesh[30].descriptor_ui | D000082082 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | adverse effects |
| mesh[30].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[31].qualifier_ui | Q000627 |
| mesh[31].descriptor_ui | D000082082 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | therapeutic use |
| mesh[31].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D053208 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Kaplan-Meier Estimate |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D015201 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Meta-Analysis as Topic |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D012189 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Retrospective Studies |
| mesh[35].qualifier_ui | Q000139 |
| mesh[35].descriptor_ui | D013959 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | chemically induced |
| mesh[35].descriptor_name | Thyroid Diseases |
| mesh[36].qualifier_ui | Q000276 |
| mesh[36].descriptor_ui | D013959 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | immunology |
| mesh[36].descriptor_name | Thyroid Diseases |
| mesh[37].qualifier_ui | Q000188 |
| mesh[37].descriptor_ui | D064726 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | drug therapy |
| mesh[37].descriptor_name | Triple Negative Breast Neoplasms |
| mesh[38].qualifier_ui | Q000235 |
| mesh[38].descriptor_ui | D064726 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | genetics |
| mesh[38].descriptor_name | Triple Negative Breast Neoplasms |
| mesh[39].qualifier_ui | Q000276 |
| mesh[39].descriptor_ui | D064726 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | immunology |
| mesh[39].descriptor_name | Triple Negative Breast Neoplasms |
| mesh[40].qualifier_ui | Q000008 |
| mesh[40].descriptor_ui | D061067 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | administration & dosage |
| mesh[40].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[41].qualifier_ui | Q000009 |
| mesh[41].descriptor_ui | D061067 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | adverse effects |
| mesh[41].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[42].qualifier_ui | Q000627 |
| mesh[42].descriptor_ui | D061067 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | therapeutic use |
| mesh[42].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[43].qualifier_ui | Q000276 |
| mesh[43].descriptor_ui | D015551 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | immunology |
| mesh[43].descriptor_name | Autoimmunity |
| mesh[44].qualifier_ui | |
| mesh[44].descriptor_ui | D005260 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | |
| mesh[44].descriptor_name | Female |
| mesh[45].qualifier_ui | |
| mesh[45].descriptor_ui | D014644 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | |
| mesh[45].descriptor_name | Genetic Variation |
| mesh[46].qualifier_ui | |
| mesh[46].descriptor_ui | D006801 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | |
| mesh[46].descriptor_name | Humans |
| mesh[47].qualifier_ui | Q000139 |
| mesh[47].descriptor_ui | D007037 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | chemically induced |
| mesh[47].descriptor_name | Hypothyroidism |
| mesh[48].qualifier_ui | Q000276 |
| mesh[48].descriptor_ui | D007037 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | immunology |
| mesh[48].descriptor_name | Hypothyroidism |
| mesh[49].qualifier_ui | Q000008 |
| mesh[49].descriptor_ui | D000082082 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | administration & dosage |
| mesh[49].descriptor_name | Immune Checkpoint Inhibitors |
| type | article |
| title | Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade |
| biblio.issue | 1 |
| biblio.volume | 12 |
| biblio.last_page | 3355 |
| biblio.first_page | 3355 |
| topics[0].id | https://openalex.org/T10158 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Cancer Immunotherapy and Biomarkers |
| topics[1].id | https://openalex.org/T11369 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9980999827384949 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2734 |
| topics[1].subfield.display_name | Pathology and Forensic Medicine |
| topics[1].display_name | Genetic factors in colorectal cancer |
| topics[2].id | https://openalex.org/T11297 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.996399998664856 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2740 |
| topics[2].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[2].display_name | Ferroptosis and cancer prognosis |
| is_xpac | False |
| apc_list.value | 3920 |
| apc_list.currency | GBP |
| apc_list.value_usd | 4808 |
| apc_paid.value | 3920 |
| apc_paid.currency | GBP |
| apc_paid.value_usd | 4808 |
| concepts[0].id | https://openalex.org/C2775949291 |
| concepts[0].level | 5 |
| concepts[0].score | 0.9562048316001892 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q20707748 |
| concepts[0].display_name | Atezolizumab |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.6591637134552002 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2780130043 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6152727603912354 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q192360 |
| concepts[2].display_name | Autoimmunity |
| concepts[3].id | https://openalex.org/C2778468042 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5768243670463562 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q273976 |
| concepts[3].display_name | Blockade |
| concepts[4].id | https://openalex.org/C8891405 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5551022291183472 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[4].display_name | Immune system |
| concepts[5].id | https://openalex.org/C197934379 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5427544116973877 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[5].display_name | Adverse effect |
| concepts[6].id | https://openalex.org/C143998085 |
| concepts[6].level | 1 |
| concepts[6].score | 0.49646931886672974 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[6].display_name | Oncology |
| concepts[7].id | https://openalex.org/C106208931 |
| concepts[7].level | 5 |
| concepts[7].score | 0.49161869287490845 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1098876 |
| concepts[7].display_name | Genome-wide association study |
| concepts[8].id | https://openalex.org/C2780851360 |
| concepts[8].level | 4 |
| concepts[8].score | 0.47384244203567505 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q21686041 |
| concepts[8].display_name | Immune checkpoint |
| concepts[9].id | https://openalex.org/C203014093 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3916901648044586 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[9].display_name | Immunology |
| concepts[10].id | https://openalex.org/C126322002 |
| concepts[10].level | 1 |
| concepts[10].score | 0.3794035315513611 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[10].display_name | Internal medicine |
| concepts[11].id | https://openalex.org/C2777701055 |
| concepts[11].level | 3 |
| concepts[11].score | 0.3410419821739197 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[11].display_name | Immunotherapy |
| concepts[12].id | https://openalex.org/C153209595 |
| concepts[12].level | 4 |
| concepts[12].score | 0.25679704546928406 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q501128 |
| concepts[12].display_name | Single-nucleotide polymorphism |
| concepts[13].id | https://openalex.org/C2780057760 |
| concepts[13].level | 4 |
| concepts[13].score | 0.25066906213760376 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q13896859 |
| concepts[13].display_name | Pembrolizumab |
| concepts[14].id | https://openalex.org/C135763542 |
| concepts[14].level | 3 |
| concepts[14].score | 0.2221783995628357 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q106016 |
| concepts[14].display_name | Genotype |
| concepts[15].id | https://openalex.org/C86803240 |
| concepts[15].level | 0 |
| concepts[15].score | 0.16081610321998596 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[15].display_name | Biology |
| concepts[16].id | https://openalex.org/C170493617 |
| concepts[16].level | 2 |
| concepts[16].score | 0.14285701513290405 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q208467 |
| concepts[16].display_name | Receptor |
| concepts[17].id | https://openalex.org/C54355233 |
| concepts[17].level | 1 |
| concepts[17].score | 0.09709760546684265 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[17].display_name | Genetics |
| concepts[18].id | https://openalex.org/C104317684 |
| concepts[18].level | 2 |
| concepts[18].score | 0.0680016577243805 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[18].display_name | Gene |
| keywords[0].id | https://openalex.org/keywords/atezolizumab |
| keywords[0].score | 0.9562048316001892 |
| keywords[0].display_name | Atezolizumab |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.6591637134552002 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/autoimmunity |
| keywords[2].score | 0.6152727603912354 |
| keywords[2].display_name | Autoimmunity |
| keywords[3].id | https://openalex.org/keywords/blockade |
| keywords[3].score | 0.5768243670463562 |
| keywords[3].display_name | Blockade |
| keywords[4].id | https://openalex.org/keywords/immune-system |
| keywords[4].score | 0.5551022291183472 |
| keywords[4].display_name | Immune system |
| keywords[5].id | https://openalex.org/keywords/adverse-effect |
| keywords[5].score | 0.5427544116973877 |
| keywords[5].display_name | Adverse effect |
| keywords[6].id | https://openalex.org/keywords/oncology |
| keywords[6].score | 0.49646931886672974 |
| keywords[6].display_name | Oncology |
| keywords[7].id | https://openalex.org/keywords/genome-wide-association-study |
| keywords[7].score | 0.49161869287490845 |
| keywords[7].display_name | Genome-wide association study |
| keywords[8].id | https://openalex.org/keywords/immune-checkpoint |
| keywords[8].score | 0.47384244203567505 |
| keywords[8].display_name | Immune checkpoint |
| keywords[9].id | https://openalex.org/keywords/immunology |
| keywords[9].score | 0.3916901648044586 |
| keywords[9].display_name | Immunology |
| keywords[10].id | https://openalex.org/keywords/internal-medicine |
| keywords[10].score | 0.3794035315513611 |
| keywords[10].display_name | Internal medicine |
| keywords[11].id | https://openalex.org/keywords/immunotherapy |
| keywords[11].score | 0.3410419821739197 |
| keywords[11].display_name | Immunotherapy |
| keywords[12].id | https://openalex.org/keywords/single-nucleotide-polymorphism |
| keywords[12].score | 0.25679704546928406 |
| keywords[12].display_name | Single-nucleotide polymorphism |
| keywords[13].id | https://openalex.org/keywords/pembrolizumab |
| keywords[13].score | 0.25066906213760376 |
| keywords[13].display_name | Pembrolizumab |
| keywords[14].id | https://openalex.org/keywords/genotype |
| keywords[14].score | 0.2221783995628357 |
| keywords[14].display_name | Genotype |
| keywords[15].id | https://openalex.org/keywords/biology |
| keywords[15].score | 0.16081610321998596 |
| keywords[15].display_name | Biology |
| keywords[16].id | https://openalex.org/keywords/receptor |
| keywords[16].score | 0.14285701513290405 |
| keywords[16].display_name | Receptor |
| keywords[17].id | https://openalex.org/keywords/genetics |
| keywords[17].score | 0.09709760546684265 |
| keywords[17].display_name | Genetics |
| keywords[18].id | https://openalex.org/keywords/gene |
| keywords[18].score | 0.0680016577243805 |
| keywords[18].display_name | Gene |
| language | en |
| locations[0].id | doi:10.1038/s41467-021-23661-4 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S64187185 |
| locations[0].source.issn | 2041-1723 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2041-1723 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Nature Communications |
| locations[0].source.host_organization | https://openalex.org/P4310319908 |
| locations[0].source.host_organization_name | Nature Portfolio |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310319908, https://openalex.org/P4310319965 |
| locations[0].source.host_organization_lineage_names | Nature Portfolio, Springer Nature |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.nature.com/articles/s41467-021-23661-4.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Nature Communications |
| locations[0].landing_page_url | https://doi.org/10.1038/s41467-021-23661-4 |
| locations[1].id | pmid:34099659 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Nature communications |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/34099659 |
| locations[2].id | pmh:oai:doaj.org/article:c4d618dc88c448e799c4accf705c951a |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].license | cc-by-sa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | https://openalex.org/licenses/cc-by-sa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021) |
| locations[2].landing_page_url | https://doaj.org/article/c4d618dc88c448e799c4accf705c951a |
| locations[3].id | pmh:oai:pubmedcentral.nih.gov:8184890 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S2764455111 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PubMed Central |
| locations[3].source.host_organization | https://openalex.org/I1299303238 |
| locations[3].source.host_organization_name | National Institutes of Health |
| locations[3].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Nat Commun |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/8184890 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5089152025 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-7859-3489 |
| authorships[0].author.display_name | Zia Khan |
| authorships[0].affiliations[0].raw_affiliation_string | Genentech, South San Francisco, CA, USA |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Zia Khan |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Genentech, South San Francisco, CA, USA |
| authorships[1].author.id | https://openalex.org/A5033829874 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-4548-7548 |
| authorships[1].author.display_name | Christian Hammer |
| authorships[1].affiliations[0].raw_affiliation_string | Genentech, South San Francisco, CA, USA |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Christian Hammer |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Genentech, South San Francisco, CA, USA |
| authorships[2].author.id | https://openalex.org/A5054119662 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-1404-5264 |
| authorships[2].author.display_name | Jonathan Carroll |
| authorships[2].affiliations[0].raw_affiliation_string | Genentech, South San Francisco, CA, USA |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Jonathan Carroll |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Genentech, South San Francisco, CA, USA |
| authorships[3].author.id | https://openalex.org/A5036861736 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Flavia Di Nucci |
| authorships[3].affiliations[0].raw_affiliation_string | Genentech, South San Francisco, CA, USA |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Flavia Di Nucci |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Genentech, South San Francisco, CA, USA |
| authorships[4].author.id | https://openalex.org/A5038609112 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Sergio Ley Acosta |
| authorships[4].affiliations[0].raw_affiliation_string | Genentech, South San Francisco, CA, USA |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Sergio Ley Acosta |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Genentech, South San Francisco, CA, USA |
| authorships[5].author.id | https://openalex.org/A5035857186 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Vidya Maiya |
| authorships[5].affiliations[0].raw_affiliation_string | Genentech, South San Francisco, CA, USA |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Vidya Maiya |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Genentech, South San Francisco, CA, USA |
| authorships[6].author.id | https://openalex.org/A5041979519 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-8233-9977 |
| authorships[6].author.display_name | Tushar Bhangale |
| authorships[6].affiliations[0].raw_affiliation_string | Genentech, South San Francisco, CA, USA |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Tushar Bhangale |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Genentech, South San Francisco, CA, USA |
| authorships[7].author.id | https://openalex.org/A5110991427 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Julie Hunkapiller |
| authorships[7].affiliations[0].raw_affiliation_string | Genentech, South San Francisco, CA, USA |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Julie Hunkapiller |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Genentech, South San Francisco, CA, USA |
| authorships[8].author.id | https://openalex.org/A5085574965 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-6132-7299 |
| authorships[8].author.display_name | Ira Mellman |
| authorships[8].affiliations[0].raw_affiliation_string | Genentech, South San Francisco, CA, USA |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Ira Mellman |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Genentech, South San Francisco, CA, USA |
| authorships[9].author.id | https://openalex.org/A5078075662 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-7285-6973 |
| authorships[9].author.display_name | Matthew L. Albert |
| authorships[9].affiliations[0].raw_affiliation_string | Genentech, South San Francisco, CA, USA |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Matthew L. Albert |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Genentech, South San Francisco, CA, USA |
| authorships[10].author.id | https://openalex.org/A5064948585 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-4393-0510 |
| authorships[10].author.display_name | Mark I. McCarthy |
| authorships[10].affiliations[0].raw_affiliation_string | Genentech, South San Francisco, CA, USA |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Mark I. McCarthy |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Genentech, South San Francisco, CA, USA |
| authorships[11].author.id | https://openalex.org/A5084564240 |
| authorships[11].author.orcid | https://orcid.org/0000-0001-5339-9906 |
| authorships[11].author.display_name | G. Scott Chandler |
| authorships[11].countries | CH |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I118019719 |
| authorships[11].affiliations[0].raw_affiliation_string | F. Hoffmann-La Roche, Basel, Switzerland |
| authorships[11].institutions[0].id | https://openalex.org/I118019719 |
| authorships[11].institutions[0].ror | https://ror.org/00by1q217 |
| authorships[11].institutions[0].type | company |
| authorships[11].institutions[0].lineage | https://openalex.org/I118019719 |
| authorships[11].institutions[0].country_code | CH |
| authorships[11].institutions[0].display_name | Roche (Switzerland) |
| authorships[11].author_position | last |
| authorships[11].raw_author_name | G. Scott Chandler |
| authorships[11].is_corresponding | True |
| authorships[11].raw_affiliation_strings | F. Hoffmann-La Roche, Basel, Switzerland |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.nature.com/articles/s41467-021-23661-4.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10158 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Cancer Immunotherapy and Biomarkers |
| related_works | https://openalex.org/W4393219064, https://openalex.org/W2263980547, https://openalex.org/W2085972006, https://openalex.org/W4361271945, https://openalex.org/W3197188017, https://openalex.org/W4200507838, https://openalex.org/W4362515066, https://openalex.org/W4362158722, https://openalex.org/W3166800855, https://openalex.org/W2575161424 |
| cited_by_count | 82 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 18 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 23 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 23 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 16 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 2 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1038/s41467-021-23661-4 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S64187185 |
| best_oa_location.source.issn | 2041-1723 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2041-1723 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Nature Communications |
| best_oa_location.source.host_organization | https://openalex.org/P4310319908 |
| best_oa_location.source.host_organization_name | Nature Portfolio |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310319908, https://openalex.org/P4310319965 |
| best_oa_location.source.host_organization_lineage_names | Nature Portfolio, Springer Nature |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.nature.com/articles/s41467-021-23661-4.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Nature Communications |
| best_oa_location.landing_page_url | https://doi.org/10.1038/s41467-021-23661-4 |
| primary_location.id | doi:10.1038/s41467-021-23661-4 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S64187185 |
| primary_location.source.issn | 2041-1723 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2041-1723 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Nature Communications |
| primary_location.source.host_organization | https://openalex.org/P4310319908 |
| primary_location.source.host_organization_name | Nature Portfolio |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310319908, https://openalex.org/P4310319965 |
| primary_location.source.host_organization_lineage_names | Nature Portfolio, Springer Nature |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.nature.com/articles/s41467-021-23661-4.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Nature Communications |
| primary_location.landing_page_url | https://doi.org/10.1038/s41467-021-23661-4 |
| publication_date | 2021-06-07 |
| publication_year | 2021 |
| referenced_works | https://openalex.org/W2110305039, https://openalex.org/W3036599100, https://openalex.org/W2783137027, https://openalex.org/W2610389172, https://openalex.org/W2889317689, https://openalex.org/W2578528809, https://openalex.org/W2179179825, https://openalex.org/W2132916434, https://openalex.org/W2997720498, https://openalex.org/W2786816161, https://openalex.org/W2993632994, https://openalex.org/W2561156916, https://openalex.org/W2577007969, https://openalex.org/W3026699635, https://openalex.org/W2777192533, https://openalex.org/W2805354595, https://openalex.org/W2946386783, https://openalex.org/W3017322331, https://openalex.org/W2893960509, https://openalex.org/W2943887705, https://openalex.org/W2897422388, https://openalex.org/W2990398119, https://openalex.org/W2760410509, https://openalex.org/W4211084027, https://openalex.org/W1933440621, https://openalex.org/W1983386138, https://openalex.org/W2777667999, https://openalex.org/W2950099124, https://openalex.org/W1844405070, https://openalex.org/W3111018742, https://openalex.org/W2531815874, https://openalex.org/W2946450286, https://openalex.org/W2896468934, https://openalex.org/W1966727713, https://openalex.org/W2598022332, https://openalex.org/W2801758857, https://openalex.org/W2547133566, https://openalex.org/W2945117574, https://openalex.org/W3010089023, https://openalex.org/W2894662039, https://openalex.org/W2152885121, https://openalex.org/W2155449815 |
| referenced_works_count | 42 |
| abstract_inverted_index | |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 93 |
| corresponding_author_ids | https://openalex.org/A5084564240, https://openalex.org/A5089152025 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 12 |
| corresponding_institution_ids | https://openalex.org/I118019719 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8600000143051147 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.97642241 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |